VNDA - Vanda Pharmaceuticals rejects sweetened bid from Future Pak
2024-05-24 16:55:06 ET
More on Vanda Pharmaceuticals
- Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript
- Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much
- Vanda reports positive Phase 3 data for motion sickness drug
- Vanda Pharmaceuticals GAAP EPS of -$0.07, revenue of $47.46M
- Seeking Alpha’s Quant Rating on Vanda Pharmaceuticals